MedPage Today November 11, 2024
Sentynl Therapeutics, Inc.

About Dr. Wendy Chung and the GUARDIAN Study

Hello, I’m Dr. Liza Squires, a Medical Consultant at Sentynl Therapeutics, a U.S.-based biopharmaceutical company focused on rare disease.

Today, I’m here with Dr. Wendy Chung, a clinical and molecular geneticist and Chief of the Department of Pediatrics at Boston Children’s Hospital and Harvard Medical School. Today, we’ll discuss the importance of advancing newborn screening with whole genome sequencing, and how healthcare providers can advocate for this important advancement.

Dr. Chung, thank you for your time. Could you share a bit about your background and work in newborn screening and genetics?

Dr. Chung

Thanks Liza, it’s good to be here. For the past 35 years, I’ve dedicated my career to genetics and...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Conferences / Podcast, Pharma / Biotech, Precision Medicine, Survey / Study, Trends
Spotiphy AI Tool Enhances Spatial Transcriptomics for Precision Medicine
Bankruptcy, Genetic Information, and Privacy — Selling Personal Information
Quibim: $50M Series A for Precision Medicine with AI-Powered Imaging Biomarkers
How DNA and hormones shape who we are
Global Genetics Study of 1.7M People Finds New Depression Risk Variants

Share This Article